William Blair Issues Positive Outlook for Labcorp Earnings

Labcorp Holdings Inc. (NYSE:LH) – Equities researchers at William Blair boosted their Q1 2026 earnings per share (EPS) estimates for shares of Labcorp in a report issued on Wednesday, October 29th. William Blair analyst A. Brackmann now expects that the medical research company will post earnings per share of $3.98 for the quarter, up from their previous forecast of $3.97. The consensus estimate for Labcorp’s current full-year earnings is $16.01 per share. William Blair also issued estimates for Labcorp’s Q3 2026 earnings at $4.42 EPS.

Other equities research analysts also recently issued reports about the stock. Barclays raised their price objective on shares of Labcorp from $275.00 to $290.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 2nd. UBS Group dropped their price target on Labcorp from $325.00 to $320.00 and set a “buy” rating for the company in a report on Wednesday, October 29th. Evercore ISI lifted their price target on Labcorp from $300.00 to $305.00 and gave the stock an “outperform” rating in a report on Friday, October 3rd. Wall Street Zen raised Labcorp from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. Finally, Truist Financial set a $320.00 target price on Labcorp in a report on Tuesday, October 14th. Eleven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $295.54.

Labcorp Stock Performance

NYSE LH opened at $258.41 on Monday. The firm has a 50-day moving average of $276.47 and a 200-day moving average of $261.81. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.55. The stock has a market cap of $21.47 billion, a PE ratio of 25.38, a P/E/G ratio of 1.59 and a beta of 0.89. Labcorp has a 52-week low of $209.38 and a 52-week high of $293.72.

Labcorp (NYSE:LH) last posted its earnings results on Tuesday, October 28th. The medical research company reported $4.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.13 by $0.05. The company had revenue of $3.56 billion during the quarter, compared to analysts’ expectations of $3.56 billion. Labcorp had a net margin of 6.21% and a return on equity of 15.85%. Labcorp’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same quarter last year, the company posted $3.50 EPS. Labcorp has set its FY 2025 guidance at 16.150-16.500 EPS.

Labcorp Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 11th. Investors of record on Wednesday, November 26th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, November 26th. Labcorp’s payout ratio is 28.29%.

Insider Activity at Labcorp

In other news, CEO Adam H. Schechter sold 5,643 shares of the business’s stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $266.78, for a total value of $1,505,439.54. Following the completion of the transaction, the chief executive officer directly owned 93,319 shares in the company, valued at approximately $24,895,642.82. The trade was a 5.70% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Der Vaart Sandra D. Van sold 3,903 shares of the business’s stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $271.42, for a total transaction of $1,059,352.26. Following the transaction, the executive vice president owned 2,274 shares of the company’s stock, valued at approximately $617,209.08. This represents a 63.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.84% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Labcorp

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in shares of Labcorp by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 9,879,225 shares of the medical research company’s stock worth $2,593,395,000 after buying an additional 156,717 shares in the last quarter. State Street Corp raised its stake in Labcorp by 0.9% during the second quarter. State Street Corp now owns 3,863,039 shares of the medical research company’s stock worth $1,014,086,000 after acquiring an additional 36,003 shares in the last quarter. Select Equity Group L.P. raised its stake in Labcorp by 39.1% during the first quarter. Select Equity Group L.P. now owns 2,220,056 shares of the medical research company’s stock worth $516,696,000 after acquiring an additional 624,099 shares in the last quarter. Geode Capital Management LLC increased its position in Labcorp by 2.2% during the 2nd quarter. Geode Capital Management LLC now owns 2,113,460 shares of the medical research company’s stock worth $552,445,000 after purchasing an additional 44,630 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in Labcorp by 2.2% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 2,000,828 shares of the medical research company’s stock worth $528,739,000 after purchasing an additional 43,509 shares in the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.

About Labcorp

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.